Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Lieve Adriaens"'
Autor:
Lillian L. Siu, A. Thomas DiCioccio, Bo Gao, Pamela A. Trail, Ana Kostic, Israel Lowy, Carrie M. Brownstein, Lieve Adriaens, Muralidhar Beeram, Ariceli A. Alfaro, Philippe L. Bedard, Amita Patnaik, Katherine Van Loon, Albiruni R. Abdul Razak, Anthony W. Tolcher, Robin Kate Kelley, Kyriakos P. Papadopoulos
Supplementary Figure 1 Total Nesvacumab (REGN910) and Total Ang2 vs Time (cycle 1) following IV infusion in Patients. Supplementary Figure 2 Serum levels of ESM1, SDF-1, PLGF-1 and sVCAM-1 following Nesvacumab (REGN910) treatment. Supplementary Figur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b578745ec3228101009b6254930a234
https://doi.org/10.1158/1078-0432.22459569.v1
https://doi.org/10.1158/1078-0432.22459569.v1
Autor:
Lillian L. Siu, A. Thomas DiCioccio, Bo Gao, Pamela A. Trail, Ana Kostic, Israel Lowy, Carrie M. Brownstein, Lieve Adriaens, Muralidhar Beeram, Ariceli A. Alfaro, Philippe L. Bedard, Amita Patnaik, Katherine Van Loon, Albiruni R. Abdul Razak, Anthony W. Tolcher, Robin Kate Kelley, Kyriakos P. Papadopoulos
Supplementary Table 1. Summary of the Most Common (>10%) Treatment-Emergent Adverse Events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95d0d66eb2e878f64baa73558c32397
https://doi.org/10.1158/1078-0432.22459566
https://doi.org/10.1158/1078-0432.22459566
Autor:
Antonio Jimeno, Adrian Harris, Russell Leek, Ana Kostic, Albert Thomas DiCioccio, Richard J. Kao, Liming Liu, Lieve Adriaens, Wells A. Messersmith, Anne Younger, Jennifer R. Diamond, Robert Matthew Strother, Patricia LoRusso, Elena Gabriela Chiorean
Supplementary Methods, Figure 1, Table 1. Supplementary Figure 1: Vascular expression of Dll4 versus CD31 in archive tumor tissue biopsies -Supplementary Table 1: Correlations between VEGFR-2 VQ and Notch1, Notch3, Dll4 Expression in Archive Samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b636fa0c01ede30739e416fd50d2d258
https://doi.org/10.1158/1078-0432.22461600
https://doi.org/10.1158/1078-0432.22461600
Autor:
Antonio Jimeno, Adrian Harris, Russell Leek, Ana Kostic, Albert Thomas DiCioccio, Richard J. Kao, Liming Liu, Lieve Adriaens, Wells A. Messersmith, Anne Younger, Jennifer R. Diamond, Robert Matthew Strother, Patricia LoRusso, Elena Gabriela Chiorean
Purpose: Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody that binds human Dll4 and disrupts Notch-mediated signaling. The main objectives of this trial were to determine the safety, dose-limiting toxicities (DLT), pharmacokinetics (PK)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00d7721596637e9f96628c49702bb009
https://doi.org/10.1158/1078-0432.c.6524832
https://doi.org/10.1158/1078-0432.c.6524832
Autor:
Lillian L. Siu, A. Thomas DiCioccio, Bo Gao, Pamela A. Trail, Ana Kostic, Israel Lowy, Carrie M. Brownstein, Lieve Adriaens, Muralidhar Beeram, Ariceli A. Alfaro, Philippe L. Bedard, Amita Patnaik, Katherine Van Loon, Albiruni R. Abdul Razak, Anthony W. Tolcher, Robin Kate Kelley, Kyriakos P. Papadopoulos
Purpose: Nesvacumab (REGN910) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Ang2 with high affinity, but shows no binding to Ang1. The main objectives of this trial were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72ba75e7ff8642325f8e0a03ff01c2a6
https://doi.org/10.1158/1078-0432.c.6524247
https://doi.org/10.1158/1078-0432.c.6524247
Autor:
Lillian L. Siu, A. Thomas DiCioccio, Bo Gao, Pamela A. Trail, Ana Kostic, Israel Lowy, Carrie M. Brownstein, Lieve Adriaens, Muralidhar Beeram, Ariceli A. Alfaro, Philippe L. Bedard, Amita Patnaik, Katherine Van Loon, Albiruni R. Abdul Razak, Anthony W. Tolcher, Robin Kate Kelley, Kyriakos P. Papadopoulos
Supplementary Data. Study entry criteria specific to patients with HCC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b1e22e2c7b7e956637fa945e369566f
https://doi.org/10.1158/1078-0432.22459572.v1
https://doi.org/10.1158/1078-0432.22459572.v1
Autor:
George D. Yancopoulos, David Sternberg, Gavin Thurston, S. M. Ansell, Julio C. Chavez, Israel Lowy, R. Advani, Johannes Duell, Susan O'Brien, Melanie Ufkin, Nathalie Fiaschi, Min Zhu, Jingjin Li, Vladimir Jankovic, Sara Hamon, Peter Gasparini, Robert Charnas, Jon E. Arnason, Srikanth R. Ambati, Jennifer R. Brown, Rajat Bannerji, Wen Zhang, Max S. Topp, Lieve Adriaens, A.J. Murphy, Andreas Rosenwald, John N. Allan
Publikováno v:
Hematological Oncology. 37:90-92
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b1fc175d62755662cc47189d6f3b6a3
https://doi.org/10.1002/hon.58_2629
https://doi.org/10.1002/hon.58_2629
Autor:
Seok-Goo Cho, Ayesha Sabir, Melanie Ufkin, Michał Taszner, Jurriaan Brouwer-Visser, Vladimir Jankovic, Mary-Margaret Keating, Steven Le Gouill, L. Andres Sirulnik, Cecilia Carpio, Tae Min Kim, Kim Won Seog, Min Zhu, Aafia Chaudhry, Siyang Leng, Miles Prince, Arancha Alonso, Srikanth R. Ambati, Don A. Stevens, Lieve Adriaens, Jingjin Li, Francesca Lorraine Wei Inng Lim, Michelle Poon
Publikováno v:
Blood. 136:28-29
BACKGROUND: Relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains an area of high unmet patient need and no curative options are currently available. Odronextamab (REGN1979) is a first-in-class, hinge-stabilized, fully human IgG4-base
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8da4338ed227b86e781ebc3c8db5669a
https://doi.org/10.1182/blood-2020-136344
https://doi.org/10.1182/blood-2020-136344
Autor:
Kyriakos P. Papadopoulos, Pamela Trail, Anthony W. Tolcher, Ana Kostic, A. Thomas DiCioccio, Robin Kate Kelley, Israel Lowy, Amita Patnaik, Ariceli Alfaro, Lillian L. Siu, Lieve Adriaens, Muralidhar Beeram, Katherine Van Loon, Philippe L. Bedard, Albiruni Ryan Abdul Razak, Bo Gao, Carrie Brownstein
Publikováno v:
Clinical Cancer Research. 22:1348-1355
Purpose: Nesvacumab (REGN910) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Ang2 with high affinity, but shows no binding to Ang1. The main objectives of this trial were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daffec72601e53d9f4772a4e480a3591
https://doi.org/10.1158/1078-0432.ccr-15-1221
https://doi.org/10.1158/1078-0432.ccr-15-1221
Autor:
Peter Gasparini, Jennifer R. Brown, Sara Hamon, Wen Zhang, Robin Joyce, Jeffrey A. Barnes, Ranjana H. Advani, Jon E. Arnason, Stephen M. Ansell, Lieve Adriaens, Vladimir Jankovic, Susan O'Brien, Raquel Deering, Johannes Duell, Srikanth R. Ambati, Kevin A. David, Max S. Topp, George D. Yancopoulos, Andrew J. Murphy, Julio C. Chavez, Jingjin Li, David Sternberg, Israel Lowy, Anfal Ibrahim, Rajat Bannerji, John N. Allan, Min Zhu, Peter Martin, Gavin Thurston, Nathalie Fiaschi, Melanie Ufkin, David M. Weinreich, Robert Charnas, Olulanu H Aina
Publikováno v:
Blood. 134:762-762
Background REGN1979 is an anti-CD20 x anti-CD3 bispecific IgG4 antibody (Ab) modified to reduce Fc binding. Engaging both targets results in CD20-specific, local T-cell activation and cytotoxicity, a mechanism of action distinct from standard anti-CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b0e83d9c32f9f8c15520aa0b4e81aa7
https://doi.org/10.1182/blood-2019-122451
https://doi.org/10.1182/blood-2019-122451